Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histiocytic sarcomas

A F Lauritzen1, E Ralfkiaer

  • 1Department of Pathology, Frederiksberg Hospital, Denmark.

Leukemia & Lymphoma
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

This review distinguishes three histiocytic malignancy types: follicular dendritic cell (FDC) sarcomas, Langerhans

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF).

Leukemia·2010
Same author

Mantle cell lymphoma in the orbital and adnexal region.

The British journal of ophthalmology·2009
Same author

Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.

Leukemia·2008
Same author

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.

Histopathology·2008
Same author

Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders.

The British journal of dermatology·2008
Same author

Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia.

Leukemia·2007
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Area of Science:

  • Oncology
  • Pathology
  • Immunohistochemistry

Background:

  • Histiocytic malignancies encompass a spectrum of rare tumors.
  • Accurate classification is crucial for prognosis and treatment.
  • Distinguishing between different subtypes remains a diagnostic challenge.

Purpose of the Study:

  • To review and categorize histiocytic malignancies based on current literature.
  • To delineate diagnostic criteria for distinct histiocytic tumor subtypes.
  • To highlight the complexities in diagnosing histiocytic sarcomas unrelated to accessory cells.

Main Methods:

  • Literature review of histiocytic malignancies.
  • Analysis of diagnostic markers including cell surface antigens (e.g., CD1a, S-100).
  • Electron microscopy for ultrastructural features (e.g., Birbeck granules).

Related Experiment Videos

  • Immunohistochemical analysis with extensive antibody panels.
  • Molecular analysis of T-cell receptor or immunoglobulin genes.

    • Main Results:

    • Three main categories identified: follicular dendritic cell (FDC) sarcomas, Langerhans' cell/interdigitating reticulum cell (LC/IRC) sarcomas, and histiocytic sarcomas (HS) unrelated to accessory cells.
    • FDC sarcomas and LC/IRC sarcomas are recognizable by specific accessory cell antigens and ultrastructural features.
    • HS unrelated to accessory cells are heterogeneous, requiring comprehensive diagnostic approaches.

    Conclusions:

    • Histiocytic malignancies can be classified into FDC sarcomas, LC/IRC sarcomas, and HS unrelated to accessory cells.
    • Diagnostic accuracy relies on identifying specific antigens, ultrastructural findings, and extensive immunohistochemistry.
    • HS unrelated to accessory cells present diagnostic complexity due to heterogeneity.